Matsuda S, Suzuki M, Miyazaki R, Cho N, Kunii K, Fukunaga K, Hayashi S, Nakamura H, Tateno M, Okada H
Department of Obstetrics and Gynecology, Juntendo University School of Medicine.
Jpn J Antibiot. 1987 May;40(5):951-68.
Clinical studies were conducted on BRL 28500 (a formulation containing 15 parts ticarcillin plus 1 part clavulanic acid). BRL 28500 was administered at doses of 1.6 g or 3.2 g b.i.d., generally for 10 days by drip infusion to patients with pelvioperitonitis or Douglas' abscess. The results obtained were summarized as follows. 1. Clinical efficacy was evaluated in 18 patients (pelvioperitonitis 14, Douglas' abscess 4), but 8 patients out of a total of 26 patients were excluded. 2. In the evaluation of clinical improvement by doctors in charge, clinical improvement rates were 44.4% on day 3, 88.2% on day 5. 3. On the basis of committee judgement, the clinical efficacy rate was 100%. 4. The bacteriological eradication rate of causative organisms was 100% in 11 patients (15 strains). Five strains out of a total of 15 strains produced beta-lactamase. 5. As a side effect, nausea was observed in 1 case. In laboratory examination, liver function abnormalities were observed in 1 case. 6. Regarding usefulness as judged by doctors in charge, the satisfactory rate was 83.3%. From the above results, it has been concluded that BRL 28500 is very useful in the treatment of pelvioperitonitis and Douglas' abscess.
对BRL 28500（一种含有15份替卡西林加1份克拉维酸的制剂）进行了临床研究。BRL 28500以1.6 g或3.2 g的剂量每日两次给药，通常通过静脉滴注给盆腔腹膜炎或Douglas窝脓肿患者使用10天。获得的结果总结如下。1. 对18例患者（盆腔腹膜炎14例，Douglas窝脓肿4例）进行了临床疗效评估，但26例患者中有8例被排除。2. 在主管医生对临床改善情况的评估中，第3天的临床改善率为44.4%，第5天为88.2%。3. 根据委员会的判断，临床有效率为100%。4. 11例患者（15株菌株）中病原体的细菌清除率为100%。15株菌株中共有5株产生β-内酰胺酶。5. 作为副作用，观察到1例恶心。在实验室检查中，观察到1例肝功能异常。6. 根据主管医生判断的有用性，满意率为83.3%。从上述结果可以得出结论，BRL 28500在盆腔腹膜炎和Douglas窝脓肿的治疗中非常有用。
